CarelonRx's DrugInsights provides a quarterly summary of Food and Drug Administration (FDA)-approved new molecular entities, formulations, and indications. We continue to closely monitor the FDA landscape to help provide our audiences with an understanding of the current drug and biologic market.

Download the PDF  to access the Q3 2023 DrugInsights update.

Get the latest news from CarelonRx